Literature DB >> 26833864

Transcranial Doppler versus transthoracic echocardiography for the detection of patent foramen ovale in patients with cryptogenic cerebral ischemia: A systematic review and diagnostic test accuracy meta-analysis.

Aristeidis H Katsanos1,2, Theodora Psaltopoulou3, Theodoros N Sergentanis3, Alexandra Frogoudaki4, Agathi-Rosa Vrettou4, Ignatios Ikonomidis4, Ioannis Paraskevaidis4, John Parissis4, Chrysa Bogiatzi5, Christina Zompola2, John Ellul6, Nikolaos Triantafyllou7, Konstantinos Voumvourakis2, Athanassios P Kyritsis1, Sotirios Giannopoulos1, Anne W Alexandrov8,9, Andrei V Alexandrov8, Georgios Tsivgoulis2,8,10.   

Abstract

OBJECTIVE: Patent foramen ovale (PFO) can be detected in up to 43% of patients with cryptogenic cerebral ischemia undergoing investigation with transesophageal echocardiography (TEE). The diagnostic value of transthoracic echocardiography (TTE) in the detection of PFO in patients with cryptogenic ischemic stroke or transient ischemic attack has not been compared with that of transcranial Doppler (TCD) using a comprehensive meta-analytical approach.
METHODS: We performed a systematic literature review to identify all prospective observational studies of patients with cryptogenic cerebral ischemia that provided both sensitivity and specificity measures of TTE, TCD, or both compared to the gold standard of TEE.
RESULTS: Our literature search identified 35 eligible studies including 3,067 patients. The pooled sensitivity and specificity for TCD was 96.1% (95% confidence interval [CI] = 93.0-97.8%) and 92.4% (95% CI = 85.5-96.1%), whereas the respective measures for TTE were 45.1% (95% CI = 30.8-60.3%) and 99.6% (95% CI = 96.5-99.9%). TTE was superior in terms of higher positive likelihood ratio values (LR+ = 106.61, 95% CI = 15.09-753.30 for TTE vs LR+ = 12.62, 95% CI = 6.52-24.43 for TCD; p = 0.043), whereas TCD demonstrated lower negative likelihood values (LR- = 0.04, 95% CI = 0.02-0.08) compared to TTE (LR- = 0.55, 95% CI = 0.42-0.72; p < 0.001). Finally, the area under the summary receiver operating curve (AUC) was significantly greater (p < 0.001) in TCD (AUC = 0.98, 95% CI = 0.97-0.99) compared to TTE studies (AUC = 0.86, 95% CI = 0.82-0.89).
INTERPRETATION: TCD is more sensitive but less specific compared to TTE for the detection of PFO in patients with cryptogenic cerebral ischemia. The overall diagnostic yield of TCD appears to outweigh that of TTE.
© 2016 American Neurological Association.

Entities:  

Mesh:

Year:  2016        PMID: 26833864     DOI: 10.1002/ana.24609

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  24 in total

Review 1.  The value of transesophageal echocardiography for embolic strokes of undetermined source.

Authors:  Aristeidis H Katsanos; Rohini Bhole; Alexandra Frogoudaki; Sotirios Giannopoulos; Nitin Goyal; Agathi-Rosa Vrettou; Ignatios Ikonomidis; Ioannis Paraskevaidis; Konstantinos Pappas; John Parissis; Athanassios P Kyritsis; Anne W Alexandrov; Nikos Triantafyllou; Marc D Malkoff; Konstantinos Voumvourakis; Andrei V Alexandrov; Georgios Tsivgoulis
Journal:  Neurology       Date:  2016-08-03       Impact factor: 9.910

2.  Detecting Patent Foramen Ovale after Cryptogenic Stroke - A Single Center Experience in Taiwan.

Authors:  Ting-Yu Lin; Yun-Ching Fu; Sheng-Ling Jan; Ming-Chih Lin
Journal:  Acta Cardiol Sin       Date:  2022-05       Impact factor: 1.800

3.  Frequency of Patent Foramen Ovale and Migraine in Patients With Cryptogenic Stroke.

Authors:  Brian H West; Nabil Noureddin; Yakov Mamzhi; Christopher G Low; Alexandra C Coluzzi; Evan J Shih; Rubine Gevorgyan Fleming; Jeffrey L Saver; David S Liebeskind; Andrew Charles; Jonathan M Tobis
Journal:  Stroke       Date:  2018-04-10       Impact factor: 7.914

4.  EACVI survey on the management of patients with patent foramen ovale and cryptogenic stroke.

Authors:  Antonello D'Andrea; Marc R Dweck; Espen Holte; Ricardo Fontes-Carvalho; Matteo Cameli; Hatem Soliman Aboumarie; Hans Christoph Diener; Kristina H Haugaa
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2021-01-22       Impact factor: 6.875

5.  Estimation of patent foramen ovale size using transcranial Doppler ultrasound in patients with ischemic stroke.

Authors:  Anna Grisold; Walter Rinner; Anna Paul; Harald Gabriel; Uros Klickovic; Michael Wolzt; Martin Krenn; Fritz Zimprich; Gabriel Bsteh; Thomas Sycha
Journal:  J Neuroimaging       Date:  2021-09-30       Impact factor: 2.324

6.  Practice advisory update summary: Patent foramen ovale and secondary stroke prevention: Report of the Guideline Subcommittee of the American Academy of Neurology.

Authors:  Steven R Messé; Gary S Gronseth; David M Kent; Jorge R Kizer; Shunichi Homma; Lee Rosterman; John D Carroll; Koto Ishida; Navdeep Sangha; Scott E Kasner
Journal:  Neurology       Date:  2020-04-29       Impact factor: 11.800

7.  Sensitivity of contrast-enhanced transthoracic echocardiography for the detection of residual shunts after percutaneous patent foramen ovale closure.

Authors:  Hongling Zhao; Qingxiong Yue; Tao Wang; Lin Wang; Zhanqi Pang; He Dong; Jian Yang; Yawen Li; Shijun Li
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.817

8.  Paroxysmal Symptoms As the First Manifestation of Multiple Sclerosis Mimicking a Transient Ischemic Attack: A Report of Two Cases.

Authors:  Yao Zhang; Siyuan Fan; Fei Han; Yan Xu
Journal:  Front Neurol       Date:  2017-11-03       Impact factor: 4.003

9.  Clinical and infarction patterns of PFO-related cryptogenic strokes and a prediction model.

Authors:  Dan He; Qiang Shi; Guangjing Xu; Zheng Hu; Xuefei Li; Qian Li; Yinping Guo; Shabei Xu; Yongbo Lin; Zhiyuan Yu; Wei Wang; Xiang Luo
Journal:  Ann Clin Transl Neurol       Date:  2018-09-24       Impact factor: 4.511

Review 10.  Epidemiology of Patent Foramen Ovale in General Population and in Stroke Patients: A Narrative Review.

Authors:  Ioanna Koutroulou; Georgios Tsivgoulis; Dimitrios Tsalikakis; Dimitris Karacostas; Nikolaos Grigoriadis; Theodoros Karapanayiotides
Journal:  Front Neurol       Date:  2020-04-28       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.